Tibsovo
Total Payments
$92.6M
Transactions
7,776
Doctors
3,150
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $41.4M | 4,324 | 2,215 |
| 2023 | $51.2M | 3,452 | 1,586 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $91.7M | 2,251 | 99.0% |
| Consulting Fee | $501,369 | 141 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $119,275 | 55 | 0.1% |
| Food and Beverage | $114,504 | 5,036 | 0.1% |
| Travel and Lodging | $94,808 | 246 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,143 | 47 | 0.1% |
Payments by Type
Research
$91.7M
2,251 transactions
General
$913,098
5,525 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase Ib/II Investigator Sponsored Study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies | Servier BioInnovation | $29.5M | 0 |
| STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | Servier BioInnovation | $24.3M | 0 |
| SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | Servier BioInnovation | $9.3M | 0 |
| A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION | Servier BioInnovation | $8.3M | 12 |
| A Phase II clinical trial of Ivosidenib for patients with clonal hematopoiesis mutations in IDH1a | Servier BioInnovation | $7.4M | 0 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | Servier BioInnovation | $6.1M | 0 |
| PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (SUNLIGHT) | Servier BioInnovation | $2.1M | 0 |
| Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | Servier BioInnovation | $1.2M | 0 |
| A PHASE II STUDY OF AG-120 IN PATIENTS WITH RECURRENT OR LOCALLY ADVANCED/METASTATIC, IDH1 MUTANT, CHONDROSARCOMA | Servier BioInnovation | $1.0M | 0 |
| STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | Servier BioInnovation | $636,969 | 0 |
| Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) | Servier BioInnovation | $596,777 | 0 |
| A PHASE I, MULTICENTER, OPEN LABEL, DOSE DE-ESCALATION AND EXPANSION STUDY OF GEMCITABINE AND CISPLATIN | Servier BioInnovation | $427,306 | 0 |
| PHASE I/II STUDY OF IDH1 INHIBITOR AG-120 AND NIVOLUMAB IN IDH1 MUTANT ADVANCED SOLID TUMORS | Servier BioInnovation | $321,886 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation | Servier BioInnovation | $243,010 | 0 |
| Longitudinal retrospective Cholangiocarcinoma chart review study | SERVIER AFFAIRES MEDICALES | $89,945 | 0 |
| A PHASE 1 STUDY OF IDH1 INHIBITION USING IVOSIDENIB AS MAINTENANCE THERAPY FOR IDH1-MUTANT MYELOID NEOPLASMS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION | Servier BioInnovation | $61,420 | 0 |
| Phase II Investigator Sponsored Study of CPX-351 in Combination with Ivosidenib for patients with IDH1 mutated Acute Myeloid Leukemia or High-Risk MDS. | Servier BioInnovation | $34,650 | 0 |
| STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS (CLARIDHY) (CLARIDHY) | SERVIER AFFAIRES MEDICALES | $16,667 | 8 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | SERVIER AFFAIRES MEDICALES | $11,555 | 7 |
| STUDY OF AG-120 (IVOSIDENIB) VS. PLACEBO IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA WITH AN IDH1 MUTATION (AGILE) | Servier BioInnovation | $7,487 | 2 |
Top Doctors Receiving Payments for Tibsovo
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Laura Lopresti | — | Ridgewood, NJ | $91.7M | 2,188 |
| , M.D | Internal Medicine | New York, NY | $46,602 | 27 |
| , M.D | Hematology | Cincinnati, OH | $41,949 | 30 |
| , MD, MA | Medical Oncology | Durham, NC | $30,420 | 22 |
| , M.D | Hematology & Oncology | Raleigh, NC | $29,646 | 33 |
| , MD | Internal Medicine | Durham, NC | $27,863 | 25 |
| , MD | Internal Medicine | Houston, TX | $24,753 | 12 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chapel Hill, NC | $23,615 | 10 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $21,056 | 12 |
| , M.D | Internal Medicine | Houston, TX | $19,685 | 19 |
| , MBBS | Hematology & Oncology | Houston, TX | $19,614 | 4 |
| , M.D | Anatomic Pathology & Clinical Pathology | Houston, TX | $19,414 | 22 |
| , M.D | Medical Oncology | Baltimore, MD | $17,940 | 18 |
| , M.D | Hematology & Oncology | Miami, FL | $15,866 | 11 |
| , M.D | Hematology & Oncology | Lincolnwood, IL | $14,613 | 15 |
| , M.D | Hematology & Oncology | Boston, MA | $13,798 | 14 |
| , M.D | Internal Medicine | Tampa, FL | $13,078 | 7 |
| , MD | Internal Medicine | Rochester, NY | $12,894 | 11 |
| , M.D | Student in an Organized Health Care Education/Training Program | Los Angeles, CA | $12,585 | 15 |
| Olatoyosi Odenike | Hematology & Oncology | Burr Ridge, IL | $12,288 | 11 |
| , M.D | Student in an Organized Health Care Education/Training Program | Ann Arbor, MI | $10,816 | 8 |
| , D.O | Hematology | Wheeling, WV | $10,489 | 15 |
| , MD | Medical Oncology | Houston, TX | $10,476 | 8 |
| , M.D | Hematology & Oncology | Ann Arbor, MI | $9,751 | 1 |
| , MD | Internal Medicine | Concord, NC | $9,733 | 3 |
Ad
Manufacturing Companies
- Servier BioInnovation $91.6M
- SERVIER PHARMACEUTICALS LLC $816,006
- SERVIER AFFAIRES MEDICALES $178,310
- LES LABORATOIRES SERVIER $31,087
Product Information
- Type Drug
- Total Payments $92.6M
- Total Doctors 3,150
- Transactions 7,776
About Tibsovo
Tibsovo is a drug associated with $92.6M in payments to 3,150 healthcare providers, recorded across 7,776 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2023 to 2024. In 2024, $41.4M was paid across 4,324 transactions to 2,215 doctors.
The most common payment nature for Tibsovo is "Unspecified" ($91.7M, 99.0% of total).
Tibsovo is associated with 20 research studies, including "Phase Ib/II Investigator Sponsored Study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies" ($29.5M).